| Market Cap | 3.21M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.91M | Forward P/E | -0.15 | EPS next Y | - | 50D Avg Chg | 12.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -81.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -97.00% |
| Recommedations | 2.00 | Quick Ratio | 0.75 | Shares Outstanding | 3.20M | 52W Low Chg | 64.00% |
| Insider Own | 0.03% | ROA | -88.01% | Shares Float | 63.77M | Beta | 0.33 |
| Inst Own | 2.41% | ROE | -391.64% | Shares Shorted/Prior | 204.48K/196.99K | Price | 0.68 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 570,343 | Target Price | 140.00 |
| Oper. Margin | - | Earnings Date | - | Volume | 1,838,184 | Change | 14.29% |
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Randall Mark Edward | 10% Owner 10% Owner | Nov 30 | Buy | 5 | 70,000 | 350,000 | 382,963 | 01/11/23 |
| Randall Kenneth Edward | 10% Owner 10% Owner | Nov 30 | Buy | 5 | 70,000 | 350,000 | 382,963 | 01/11/23 |
| Renaissance Capital Partners L... | 10% Owner 10% Owner | Nov 30 | Buy | 5 | 70,000 | 350,000 | 136,834 | 01/11/23 |
| Randall Kenneth Edward | 10% Owner 10% Owner | May 24 | Buy | 1.15 | 20,803 | 23,923 | 100,418 | 07/14/22 |